Daphne Quimi - 06 Jan 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact for Daphne Quimi
Issuer symbol
AMLX
Transactions as of
06 Jan 2022
Net transactions value
$0
Form type
3
Filing time
06 Jan 2022, 16:05:52 UTC
Previous filing
04 Jan 2022
Next filing
19 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AMLX Stock Option (Right to Buy) 06 Jan 2022 Common Stock 81,100 $7.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20,296 of the shares subject to such option shall vest and become exercisable on June 21, 2022 and the remainder of the shares vest in monthly installments of 1,689 shares thereafter.